Base de dados : MEDLINE
Pesquisa : D02.241.223.601.600 [Categoria DeCS]
Referências encontradas : 6140 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 614 ir para página                         

  1 / 6140 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29378209
[Au] Autor:Zhu M; Tian Y; Zhang H; Ma X; Shang B; Zhang J; Jiao Y; Zhang Y; Hu J; Wang Y
[Ad] Endereço:Department of Psychiatry and Psychology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
[Ti] Título:Methylphenidate ameliorates hypoxia-induced mitochondrial damage in human neuroblastoma SH-SY5Y cells through inhibition of oxidative stress.
[So] Source:Life Sci;197:40-45, 2018 Mar 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Methylphenidate (MPH) is a dopamine-reuptake inhibitor approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). Nonetheless, the cellular and molecular mechanisms of MPH are still unknown. We attempt to determine whether MPH protect neuron cells against oxidative stress by using human neuroblastoma SH-SY5Y cells. MAIN METHODS: The SH-SY5Y cells were cultured in normoxic and hypoxic conditions in the presence of different doses of MPH. Then, reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD) and adenosine triphosphate (ATP) production were quantitatively measured by using flow cytometry or spectrophotometry. The mitochondrial ultrastructure of the cells was observed by electron microscope, and the function of mitochondrial was evaluated by measuring mitochondrial membrane potential (MMP) using flow cytometry. The levels of SOD and heme oxygenase-1 (HO-1) proteins were detected by Western blot. KEY FINDINGS: We found that low doses of MPH treatment (50-500 ng/mL) led to decreased ROS and MDA production (P<0.05), increased GSH and SOD as well as ATP concentration (P<0.05) in hypoxic SH-SY5Y cells. Additionally, low doses of MPH significantly inhibited mitochondrial swelling and decreased the percentage of JC-1 monomer positive cells. However, we did not observe the same effects of MPH in normoxia. SIGNIFICANCE: Our results show that low doses of MPH play protective roles in maintaining mitochondrial homeostasis in response to hypoxia-induced oxidative stress. Our findings may provide novel insight into the mechanisms of MPH in the treatment of ADHD, and shed light on the disease mechanisms of ADHD.
[Mh] Termos MeSH primário: Metilfenidato/farmacologia
Mitocôndrias/metabolismo
Neuroblastoma/metabolismo
Estresse Oxidativo/efeitos dos fármacos
[Mh] Termos MeSH secundário: Trifosfato de Adenosina/metabolismo
Hipóxia Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Heme Oxigenase-1/metabolismo
Seres Humanos
Mitocôndrias/patologia
Proteínas de Neoplasias/metabolismo
Neuroblastoma/tratamento farmacológico
Neuroblastoma/patologia
Espécies Reativas de Oxigênio/metabolismo
Superóxido Dismutase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neoplasm Proteins); 0 (Reactive Oxygen Species); 207ZZ9QZ49 (Methylphenidate); 8L70Q75FXE (Adenosine Triphosphate); EC 1.14.14.18 (HMOX1 protein, human); EC 1.14.14.18 (Heme Oxygenase-1); EC 1.15.1.1 (Superoxide Dismutase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  2 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449914
[Au] Autor:Kalil Neto F; Nunes ML
[Ad] Endereço:Division of Neurology, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
[Ti] Título:Evaluation of sleep organization in patients with attention deficit hyperactivity disorder (ADHD) and ADHD as a comorbidity of epilepsy.
[So] Source:Sleep Med;33:91-96, 2017 May.
[Is] ISSN:1878-5506
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE/BACKGROUND: Epilepsy or attention deficit hyperactivity disorder (ADHD) can influence sleep organization in different ways. The aim of this study was to evaluate sleep organization in children and adolescents with ADHD and epilepsy, and to analyze the influence of methylphenidate. METHODS: This was an observational, cross-sectional study of children and adolescents with epilepsy, who were seizure free for at least three months, and were also diagnosed with ADHD. They were selected from the epilepsy and child neurology outpatient clinic of a university hospital in Brazil. After sample size calculation, patients were consecutively included into four different groups, with 21 patients each: epilepsy + ADHD using methylphenidate, epilepsy + ADHD not using methylphenidate, only ADHD, and a healthy control group. All participants were evaluated with the Sleep Disturbance Scale for Children (SDSC) and monitored with actigraphy for five nights/days. RESULTS: Actigraphic analysis showed a higher number of night awakenings in the epilepsy + ADHD groups; they were most prominent in the group without methylphenidate (p = 0.001). Parental reports demonstrated a higher risk for sleep disturbances in the epilepsy + ADHD without methylphenidate and the ADHD groups (p < 0.001). CONCLUSION: Primary ADHD as a comorbidity of epilepsy impairs sleep organization in children, and the use of short-acting methylphenidate seems to improve it. Both objective (actigraphic) and subjective (SDSC) measures showed significant sleep alterations between primary ADHD and ADHD as a comorbidity of epilepsy; this was most prominent in the group without methylphenidate.
[Mh] Termos MeSH primário: Transtorno do Deficit de Atenção com Hiperatividade/complicações
Epilepsia/complicações
Metilfenidato/efeitos adversos
Transtornos do Sono-Vigília/tratamento farmacológico
Sono/efeitos dos fármacos
[Mh] Termos MeSH secundário: Actigrafia/métodos
Adolescente
Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia
Brasil/epidemiologia
Estimulantes do Sistema Nervoso Central/efeitos adversos
Estimulantes do Sistema Nervoso Central/farmacologia
Criança
Comorbidade
Estudos Transversais
Epilepsia/diagnóstico
Epilepsia/tratamento farmacológico
Epilepsia/epidemiologia
Feminino
Seres Humanos
Masculino
Metilfenidato/farmacologia
Transtornos do Sono-Vigília/epidemiologia
Transtornos do Sono-Vigília/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 207ZZ9QZ49 (Methylphenidate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  3 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28744604
[Au] Autor:Dela Peña I; Dela Peña IJ; de la Peña JB; Kim HJ; Shin CY; Han DH; Kim BN; Ryu JH; Cheong JH
[Ad] Endereço:Department of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, 26-21 Kongreung-2-dong, Hwarangro-815, Nowon-gu, Seoul, 139-742, Republic of Korea. idelapena@llu.edu.
[Ti] Título:Methylphenidate and Atomoxetine-Responsive Prefrontal Cortical Genetic Overlaps in "Impulsive" SHR/NCrl and Wistar Rats.
[So] Source:Behav Genet;47(5):564-580, 2017 Sep.
[Is] ISSN:1573-3297
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Impulsivity, the predisposition to act prematurely without foresight, is associated with a number of neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). Identifying genetic underpinnings of impulsive behavior may help decipher the complex etiology and neurobiological factors of disorders marked by impulsivity. To identify potential genetic factors of impulsivity, we examined common differentially expressed genes (DEGs) in the prefrontal cortex (PFC) of adolescent SHR/NCrl and Wistar rats, which showed marked decrease in preference for the large but delayed reward, compared with WKY/NCrl rats, in the delay discounting task. Of these DEGs, we examined drug-responsive transcripts whose mRNA levels were altered following treatment (in SHR/NCrl and Wistar rats) with drugs that alleviate impulsivity, namely, the ADHD medications methylphenidate and atomoxetine. Prefrontal cortical genetic overlaps between SHR/NCrl and Wistar rats in comparison with WKY/NCrl included genes associated with transcription (e.g., Btg2, Fos, Nr4a2), synaptic plasticity (e.g., Arc, Homer2), and neuron apoptosis (Grik2, Nmnat1). Treatment with methylphenidate and/or atomoxetine increased choice of the large, delayed reward in SHR/NCrl and Wistar rats and changed, in varying degrees, mRNA levels of Nr4a2, Btg2, and Homer2, genes with previously described roles in neuropsychiatric disorders characterized by impulsivity. While further studies are required, we dissected potential genetic factors that may influence impulsivity by identifying genetic overlaps in the PFC of "impulsive" SHR/NCrl and Wistar rats. Notably, these are also drug-responsive transcripts which may be studied further as biomarkers to predict response to ADHD drugs, and as potential targets for the development of treatments to improve impulsivity.
[Mh] Termos MeSH primário: Comportamento Impulsivo/efeitos dos fármacos
Comportamento Impulsivo/fisiologia
Córtex Pré-Frontal/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Cloridrato de Atomoxetina/metabolismo
Transtorno do Deficit de Atenção com Hiperatividade/genética
Comportamento de Escolha
Modelos Animais de Doenças
Masculino
Metilfenidato/metabolismo
Córtex Pré-Frontal/metabolismo
Ratos
Ratos Endogâmicos SHR/genética
Ratos Endogâmicos SHR/metabolismo
Ratos Endogâmicos WKY/genética
Ratos Endogâmicos WKY/metabolismo
Ratos Wistar/genética
Ratos Wistar/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
207ZZ9QZ49 (Methylphenidate); 57WVB6I2W0 (Atomoxetine Hydrochloride)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1007/s10519-017-9861-3


  4 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452866
[Au] Autor:Connell CJW; Thompson B; Turuwhenua J; Srzich A; Gant N
[Ad] Endereço:1Department of Exercise Sciences, Centre for Brain Research, University of Auckland, Auckland, NEW ZEALAND; 2School of Optometry and Vision Science, University of Waterloo, Ontario, CANADA; and 3Department of Optometry and Vision Science, University of Auckland, Auckland, NEW ZEALAND.
[Ti] Título:Effects of Dopamine and Norepinephrine on Exercise-induced Oculomotor Fatigue.
[So] Source:Med Sci Sports Exerc;49(9):1778-1788, 2017 Sep.
[Is] ISSN:1530-0315
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Fatigue-induced impairments in the control of eye movements are detectable via reduced eye movement velocity after a bout of prolonged, strenuous exercise. Slower eye movements caused by neural fatigue within the oculomotor system can be prevented by caffeine, and the upregulation of central catecholamines may be responsible for this effect. This study explored the individual contribution of dopamine and norepinephrine to fatigue-related impairments in oculomotor control. METHODS: The influence of a dopamine reuptake inhibitor (methylphenidate) and a norepinephrine reuptake inhibitor (reboxetine) was assessed in 12 cyclists performing 180 min of stationary cycling within a placebo-controlled crossover design. Eye movement kinematics (saccades, smooth pursuit, and optokinetic nystagmus) were measured using infrared oculography. Visual attention was assessed with overt and covert spatial attention tasks. RESULTS: Exercise-induced fatigue was associated with a 6% ± 8% reduction in the peak velocity of visually guided, reflexive prosaccades. Importantly, both dopamine reuptake inhibition and norepinephrine reuptake inhibition prevented fatigue-related decrements in the peak velocity of prosaccades. Pursuit eye movements, optokinetic nystagmus, and visual attention tasks were unaffected by exercise or drug treatments. CONCLUSION: Overall, our findings suggest that alterations in norepinephrinergic and dopaminergic neurotransmission are linked with the development of fatigue within circuits that control eye movements. Psychiatric medications that target central catecholamines can exert a protective effect on eye movements after prolonged exercise.
[Mh] Termos MeSH primário: Dopamina/fisiologia
Exercício/fisiologia
Movimentos Oculares/fisiologia
Fadiga/fisiopatologia
Norepinefrina/fisiologia
[Mh] Termos MeSH secundário: Inibidores da Captação Adrenérgica/farmacologia
Adulto
Estudos Cross-Over
Inibidores da Captação de Dopamina/farmacologia
Movimentos Oculares/efeitos dos fármacos
Feminino
Seres Humanos
Masculino
Metilfenidato/farmacologia
Meia-Idade
Morfolinas/farmacologia
Transmissão Sináptica
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic Uptake Inhibitors); 0 (Dopamine Uptake Inhibitors); 0 (Morpholines); 207ZZ9QZ49 (Methylphenidate); 947S0YZ36I (reboxetine); VTD58H1Z2X (Dopamine); X4W3ENH1CV (Norepinephrine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1249/MSS.0000000000001307


  5 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743598
[Au] Autor:Ebihara K; Fujiwara H; Awale S; Dibwe DF; Araki R; Yabe T; Matsumoto K
[Ad] Endereço:Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
[Ti] Título:Decrease in endogenous brain allopregnanolone induces autism spectrum disorder (ASD)-like behavior in mice: A novel animal model of ASD.
[So] Source:Behav Brain Res;334:6-15, 2017 09 15.
[Is] ISSN:1872-7549
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Autism spectrum disorder (ASD) is a neurodevelopmental disorder with core symptoms of social impairments and restrictive repetitive behaviors. Recent evidence has implicated a dysfunction in the GABAergic system in the pathophysiology of ASD. We investigated the role of endogenous allopregnanolone (ALLO), a neurosteroidal positive allosteric modulator of GABA receptors, in the regulation of ASD-like behavior in male mice using SKF105111 (SKF), an inhibitor of type I and type II 5α-reductase, a rate-limiting enzyme of ALLO biosynthesis. SKF impaired sociability-related performance, as analyzed by three different tests; i.e., the 3-chamber test and social interaction in the open field and resident-intruder tests, without affecting olfactory function elucidated by the buried food test. SKF also induced repetitive grooming behavior without affecting anxiety-like behavior. SKF had no effect on short-term spatial working memory or long-term fear memory, but enhanced latent learning ability in male mice. SKF-induced ASD-like behavior in male mice was abolished by the systemic administration of ALLO (1mg/kg, i.p.) and methylphenidate (MPH: 2.5mg/kg, i.p.), a dopamine transporter inhibitor. The effects of SKF on brain ALLO contents in male mice were reversed by ALLO, but not MPH. On the other hand, SKF failed to induce ASD-like behavior or a decline in brain ALLO contents in female mice. These results suggest that ALLO regulates episodes of ASD-like behavior by positively modulating the function of GABA receptors linked to the dopaminergic system. Moreover, a sex-dependently induced decrease in brain ALLO contents may provide an animal model to study the main features of ASD.
[Mh] Termos MeSH primário: Androstanos
Transtorno do Espectro Autista/metabolismo
Encéfalo/metabolismo
Modelos Animais de Doenças
Pregnanolona/deficiência
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase/farmacologia
Animais
Ansiedade/metabolismo
Transtorno do Espectro Autista/tratamento farmacológico
Transtorno do Espectro Autista/psicologia
Encéfalo/efeitos dos fármacos
Medo/fisiologia
Feminino
Asseio Animal/fisiologia
Aprendizagem/fisiologia
Masculino
Memória/fisiologia
Metilfenidato/farmacologia
Camundongos Endogâmicos ICR
Psicotrópicos/farmacologia
Caracteres Sexuais
Comportamento Social
Comportamento Estereotipado/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Androstanes); 0 (Psychotropic Drugs); 0 (SKF 105111); 207ZZ9QZ49 (Methylphenidate); BXO86P3XXW (Pregnanolone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  6 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28746699
[Au] Autor:Man KKC; Coghill D; Chan EW; Lau WCY; Hollis C; Liddle E; Banaschewski T; McCarthy S; Neubert A; Sayal K; Ip P; Schuemie MJ; Sturkenboom MCJM; Sonuga-Barke E; Buitelaar J; Carucci S; Zuddas A; Kovshoff H; Garas P; Nagy P; Inglis SK; Konrad K; Häge A; Rosenthal E; Wong ICK
[Ad] Endereço:Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
[Ti] Título:Association of Risk of Suicide Attempts With Methylphenidate Treatment.
[So] Source:JAMA Psychiatry;74(10):1048-1055, 2017 Oct 01.
[Is] ISSN:2168-6238
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeutic use and suicide is unclear. Objective: To investigate the association between methylphenidate and the risk of suicide attempts. Design, Setting, and Participants: A population-based, electronic medical records database from the Hong Kong Clinical Data Analysis & Reporting System was used to identify 25 629 individuals aged 6 to 25 years who were treated with methylphenidate between January 1, 2001, and December 31, 2015. Those who had attempted suicide were included in the analysis. A self-controlled case series design was used to control for time-invariant characteristics of the patients. Main Outcomes and Measures: Relative incidence of suicide attempt during periods when patients were exposed to methylphenidate compared with nonexposed periods. Results: Among 25 629 patients with methylphenidate prescriptions, 154 had their first recorded suicide attempt within the study period; of these individuals, 111 (72.1%) were male; mean (SD) age at baseline was 7.15 (2.19) years. The overall incidence of suicide attempts during methylphenidate treatment was 9.27 per 10 000 patient-years. An increased risk of suicide attempts was detected during the 90-day period before methylphenidate was initiated, with an incidence rate ratio (IRR) of 6.55 (95% CI, 3.37-12.72). The IRR remained elevated during the first 90 days of treatment (IRR, 3.91; 95% CI, 1.62-9.42) before returning to baseline levels during ongoing treatment (IRR, 1.35; 95% CI, 0.77-2.38). When the risk during the first 90 days of treatment was compared with the 90 days preceding first treatment, the incidence of suicide attempts was not elevated (IRR, 0.78; 95% CI, 0.26-2.35). Conclusions and Relevance: The incidence of suicide attempts was higher in the period immediately before the start of methylphenidate treatment. The risk remained elevated immediately after the start of methylphenidate treatment and returned to baseline levels during continuation of methylphenidate treatment. The observed higher risk of suicide attempts before treatment may reflect emerging psychiatric symptoms that trigger medical consultations that result in a decision to begin ADHD treatment. Therefore, this study's results do not support a causal association between methylphenidate treatment and suicide attempts.
[Mh] Termos MeSH primário: Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Metilfenidato
Suicídio
[Mh] Termos MeSH secundário: Adolescente
Transtorno do Deficit de Atenção com Hiperatividade/psicologia
Estimulantes do Sistema Nervoso Central/administração & dosagem
Estimulantes do Sistema Nervoso Central/efeitos adversos
Criança
Feminino
Seres Humanos
Incidência
Masculino
Metilfenidato/administração & dosagem
Metilfenidato/efeitos adversos
Avaliação de Resultados da Assistência ao Paciente
Estatística como Assunto
Suicídio/prevenção & controle
Suicídio/psicologia
Tentativa de Suicídio/psicologia
Tentativa de Suicídio/estatística & dados numéricos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 207ZZ9QZ49 (Methylphenidate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171207
[Lr] Data última revisão:
171207
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1001/jamapsychiatry.2017.2183


  7 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28466613
[Au] Autor:Cohen HA; Savitsky B; Ashkenasi A; Hoshen M
[Ad] Endereço:Pediatric Ambulatory Community Clinic, Petah Tikva, Israel.
[Ti] Título:Seasonality of Methylphenidate Administration among Children in Israel.
[So] Source:Isr Med Assoc J;18(11):655-660, 2016 Nov.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention, impulsivity and hyperactivity. Recently, increases in ADHD prevalence and methylphenidate use have been reported. There is evidence that children and adolescents use ADHD medication only during the school year. OBJECTIVES: To investigate trends in methylphenidate dispensing over a period of 3 years (2010-2012) at the monthly level and to investigate whether there is any monthly variation, especially during the summer season. METHODS: The database of Clalit Health Services (the largest of the four health funds in Israel) was used to identify (i) patients aged 6-17 years with a diagnosis of ADHD, and (ii) methylpenidate dispensation during the period 2010-2012. RESULTS: Among children aged 6-17 years diagnosed with ADHD, 43% were treated with methylphenidate. For the period 2010 to 2012 there was an annual drop in methylphenidate dispensing, beginning in June and continuing through the 2 months of summer vacation, with a 2.5-fold reduction from July as compared to May. This decline was consistently followed by a rise in medications dispensed starting August. A similar small drop was observed during the Passover school vacation. The summer drop decreased over the years. CONCLUSIONS: Our findings showed a decrease in the number of methylphenidate prescriptions dispensed during the summer months and Passover as compared to the rest of the year. However, this phenomenon appears to be decreasing. Given that ADHD is a chronic disease state that can effectively be managed with pharmacotherapy, discontinuation of treatment may be harmful for patients and should be considered only on a patient-by-patient basis.
[Mh] Termos MeSH primário: Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Estimulantes do Sistema Nervoso Central/administração & dosagem
Metilfenidato/administração & dosagem
Estações do Ano
[Mh] Termos MeSH secundário: Adolescente
Estimulantes do Sistema Nervoso Central/uso terapêutico
Criança
Estudos de Coortes
Feminino
Seres Humanos
Israel
Masculino
Metilfenidato/uso terapêutico
Prevalência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 207ZZ9QZ49 (Methylphenidate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  8 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28762862
[Au] Autor:Mattingly GW; Wilson J; Rostain AL
[Ad] Endereço:a Washington University School of Medicine , Department of Psychiatry and Behavioral Neurosciences , St. Charles , MO , USA.
[Ti] Título:A clinician's guide to ADHD treatment options.
[So] Source:Postgrad Med;129(7):657-666, 2017 Sep.
[Is] ISSN:1941-9260
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Attention deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition of children and adolescents that often persists into adulthood. Primary care physicians are commonly the first to diagnosis ADHD and initiate a treatment plan with the patient. Guidelines recommend psychostimulant treatment as a first-line therapy in the management plan because it has a substantial impact on alleviating the core symptoms of ADHD. The recent development of a variety of methylphenidate and amphetamine formulations provides many options to meet individual patient lifestyle needs. Liquid, chewable, sprinkled capsule, wearable patch, and orally disintegrating tablet formulations are currently available for patients who may be noncompliant with or have difficulty swallowing traditional pills. This review provides a resource for physicians to identify the stimulant delivery formulation that best suits the patient. Formulations in development are also discussed.
[Mh] Termos MeSH primário: Anfetaminas/uso terapêutico
Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Estimulantes do Sistema Nervoso Central/uso terapêutico
Metilfenidato/uso terapêutico
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Adolescente
Criança
Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Amphetamines); 0 (Central Nervous System Stimulants); 207ZZ9QZ49 (Methylphenidate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1080/00325481.2017.1354648


  9 / 6140 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28682529
[Au] Autor:Stuckelman ZD; Mulqueen JM; Ferracioli-Oda E; Cohen SC; Coughlin CG; Leckman JF; Bloch MH
[Ad] Endereço:Yale Child Study Center, New Haven, Connecticut, USA.
[Ti] Título:Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
[So] Source:J Clin Psychiatry;78(6):e648-e655, 2017 Jun.
[Is] ISSN:1555-2101
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Irritability is listed as a common side effect of psychostimulant medications. However, psychostimulants have been demonstrated as an effective treatment in reducing irritability and aggression in children with attention-deficit/hyperactivity disorder (ADHD). The goal of this study was to quantify the risk of irritability as a side effect of psychostimulant treatment for ADHD. DATA SOURCES AND STUDY SELECTION: A PubMed search was conducted on August 18, 2013, to identify all double-blind, randomized, placebo-controlled trials published in English examining the efficacy of psychostimulant medications in the treatment of children with ADHD. Trials were excluded if (1) they required additional psychiatric or medical comorbidity in addition to ADHD, (2) they involved fewer than 20 subjects (parallel group trials), or (3) children received psychostimulant medication for less than 1 week. DATA EXTRACTION: A fixed-effects meta-analysis was used to examine the risk ratio of irritability reported as a side effect in children treated with psychostimulants compared to placebo. Stratified subgroup analysis and meta-regression were used to examine the effects of stimulant type, dosage, duration of use, and trial design on the measured risk of irritability. RESULTS: From 92 potentially eligible trials, the meta-analysis identified 32 trials involving 3,664 children with ADHD that reported data on irritability as a side effect. The relative risk of irritability significantly differed between psychostimulant classes (test for subgroup differences χ²1 = 7.6, P = .006). Methylphenidate derivatives were associated with a significantly decreased risk of irritability compared to placebo (risk ratio [RR] = 0.89 [95% CI, 0.82 to 0.96], z = -2.87, P = .004, k = 32, I² = 50%), whereas amphetamine derivatives were associated with a significantly increased risk of irritability (RR = 2.90 [95% CI, 1.26 to 6.71], z = 2.5, P = .01, k = 5, I² = 0%). CONCLUSIONS: This meta-analysis suggests an increased risk of irritability may be confined to amphetamine-derived psychostimulants. Future meta-analyses examining the effects of amphetamine and methylphenidate derivatives on irritability as a continuous measure, as well as head-to-head trials between methylphenidate and amphetamine derivatives examining effects on irritability, will be important to replicate the findings of this meta-analysis.
[Mh] Termos MeSH primário: Anfetamina/efeitos adversos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Estimulantes do Sistema Nervoso Central/efeitos adversos
Humor Irritável/efeitos dos fármacos
Metilfenidato/efeitos adversos
[Mh] Termos MeSH secundário: Criança
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 207ZZ9QZ49 (Methylphenidate); CK833KGX7E (Amphetamine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE


  10 / 6140 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28640076
[Au] Autor:Zhang WT; Wang YF
[Ad] Endereço:aDepartment of Neurosurgery, The People's Hospital of Yan'an, Yan'an bDepartment of Neurosurgery, The People's Hospital of Ningxia, Yinchuan, China.
[Ti] Título:Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury.
[So] Source:Medicine (Baltimore);96(25):e6960, 2017 Jun.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study aimed to evaluate the effect of methylphenidate for treating mental sequelae after traumatic brain injury (TBI). METHODS: Thirty-six patients with TBI were randomly divided into the intervention group and placebo group. The participants in the intervention group received methylphenidate, while subjects in the placebo group were administered a placebo. This study was conducted from January 2014 to December 2016. The outcome measurements included Mental Fatigue Scale, Choice Reaction Time, Compensatory Tracking Task, Mental Arithmetic Test, Digit Symbol Substitution Test, Mini-Mental State Examination (MMSE), Beck Depression Inventory (BDI), and Hamilton Rating Scale for Depression. In addition, safety was also recorded and assessed. RESULTS: A total of 33 subjects completed the study. Methylphenidate showed greater efficacy than placebo, with decreased scores on the Mental Fatigue Scale, Choice Reaction Time, and Compensatory Tracking Task in the intervention group compared to the placebo group (P < .01, respectively). Furthermore, increased scores on the Mental Arithmetic Test, Digit Symbol Substitution Test, and MMSE in the intervention group, compared to those in the placebo group (P < .01 respectively), were observed. In addition, a significant difference in the scores on the BDI (P = .04) and Hamilton Rating Scale for Depression (P = .005) was observed between the 2 groups. The safety at the end of the 30 week-treatment was similar between the 2 groups (P > .05). CONCLUSION: The results of this study demonstrated that methylphenidate could effectively improve mental fatigue and cognitive functions in patients with TBI.
[Mh] Termos MeSH primário: Lesões Encefálicas Traumáticas/tratamento farmacológico
Lesões Encefálicas Traumáticas/psicologia
Transtornos Cognitivos/tratamento farmacológico
Fadiga Mental/tratamento farmacológico
Metilfenidato/uso terapêutico
Psicotrópicos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Lesões Encefálicas Traumáticas/complicações
Transtornos Cognitivos/etiologia
Depressão/tratamento farmacológico
Depressão/etiologia
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Conceitos Matemáticos
Fadiga Mental/etiologia
Entrevista Psiquiátrica Padronizada
Testes Neuropsicológicos
Escalas de Graduação Psiquiátrica
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Psychotropic Drugs); 207ZZ9QZ49 (Methylphenidate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006960



página 1 de 614 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde